Industry Growth Insights published a new data on “Orphan Drugs Market”. The research report is titled “Orphan Drugs Market research by Types (Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic disorders, Endocrinology, Infectious diseases, Others), By Applications (Hospital Pharmacies, Speciality Pharmacies, Retail pharmacies, Others), By Players/Companies Novartis, Bristol-Myers Squibb, Celgene, Roche, Pfizer, Sanofi, Alexion Pharmaceuticals, Eli Lilly, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Bayer, GlaxoSmithKline, Merck, Johnson & Johnson, Biogen, Shire, Amgen”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Orphan Drugs Market Research Report
By Type
Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic disorders, Endocrinology, Infectious diseases, Others
By Application
Hospital Pharmacies, Speciality Pharmacies, Retail pharmacies, Others
By Companies
Novartis, Bristol-Myers Squibb, Celgene, Roche, Pfizer, Sanofi, Alexion Pharmaceuticals, Eli Lilly, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Bayer, GlaxoSmithKline, Merck, Johnson & Johnson, Biogen, Shire, Amgen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Orphan Drugs Market Report Segments:
The global Orphan Drugs market is segmented on the basis of:
Types
Oncology, Gastrointestinal, Pulmonary, Neurology, Hematology, Cardio-vascular, Metabolic disorders, Endocrinology, Infectious diseases, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Speciality Pharmacies, Retail pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Bristol-Myers Squibb
- Celgene
- Roche
- Pfizer
- Sanofi
- Alexion Pharmaceuticals
- Eli Lilly
- Novo Nordisk
- AstraZeneca
- Eisai
- Daiichi Sankyo
- Bayer
- GlaxoSmithKline
- Merck
- Johnson & Johnson
- Biogen
- Shire
- Amgen
Highlights of The Orphan Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oncology
- Gastrointestinal
- Pulmonary
- Neurology
- Hematology
- Cardio-vascular
- Metabolic disorders
- Endocrinology
- Infectious diseases
- Others
- By Application:
- Hospital Pharmacies
- Speciality Pharmacies
- Retail pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Orphan Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Orphan drugs are medications that are designed to treat rare diseases or conditions. These medications may not be available in all countries, and they may have a higher cost than other medications. Orphan drugs are important because they can help to improve the lives of people who suffer from these conditions.
Some of the key players operating in the orphan drugs market are Novartis, Bristol-Myers Squibb, Celgene, Roche, Pfizer, Sanofi, Alexion Pharmaceuticals, Eli Lilly, Novo Nordisk, AstraZeneca, Eisai, Daiichi Sankyo, Bayer, GlaxoSmithKline, Merck, Johnson & Johnson, Biogen, Shire, Amgen.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Orphan Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Orphan Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Orphan Drugs Market - Supply Chain
4.5. Global Orphan Drugs Market Forecast
4.5.1. Orphan Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Orphan Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Orphan Drugs Market Absolute $ Opportunity
5. Global Orphan Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Orphan Drugs Market Size and Volume Forecast by Type
5.3.1. Oncology
5.3.2. Gastrointestinal
5.3.3. Pulmonary
5.3.4. Neurology
5.3.5. Hematology
5.3.6. Cardio-vascular
5.3.7. Metabolic disorders
5.3.8. Endocrinology
5.3.9. Infectious diseases
5.3.10. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Orphan Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Orphan Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Speciality Pharmacies
6.3.3. Retail pharmacies
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Orphan Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Orphan Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Orphan Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Orphan Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Orphan Drugs Demand Share Forecast, 2019-2026
9. North America Orphan Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Orphan Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Orphan Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Speciality Pharmacies
9.4.3. Retail pharmacies
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Orphan Drugs Market Size and Volume Forecast by Type
9.7.1. Oncology
9.7.2. Gastrointestinal
9.7.3. Pulmonary
9.7.4. Neurology
9.7.5. Hematology
9.7.6. Cardio-vascular
9.7.7. Metabolic disorders
9.7.8. Endocrinology
9.7.9. Infectious diseases
9.7.10. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Orphan Drugs Demand Share Forecast, 2019-2026
10. Latin America Orphan Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Orphan Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Orphan Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Speciality Pharmacies
10.4.3. Retail pharmacies
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Orphan Drugs Market Size and Volume Forecast by Type
10.7.1. Oncology
10.7.2. Gastrointestinal
10.7.3. Pulmonary
10.7.4. Neurology
10.7.5. Hematology
10.7.6. Cardio-vascular
10.7.7. Metabolic disorders
10.7.8. Endocrinology
10.7.9. Infectious diseases
10.7.10. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Orphan Drugs Demand Share Forecast, 2019-2026
11. Europe Orphan Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Orphan Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Orphan Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Speciality Pharmacies
11.4.3. Retail pharmacies
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Orphan Drugs Market Size and Volume Forecast by Type
11.7.1. Oncology
11.7.2. Gastrointestinal
11.7.3. Pulmonary
11.7.4. Neurology
11.7.5. Hematology
11.7.6. Cardio-vascular
11.7.7. Metabolic disorders
11.7.8. Endocrinology
11.7.9. Infectious diseases
11.7.10. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Orphan Drugs Demand Share, 2019-2026
12. Asia Pacific Orphan Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Orphan Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Orphan Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Speciality Pharmacies
12.4.3. Retail pharmacies
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Orphan Drugs Market Size and Volume Forecast by Type
12.7.1. Oncology
12.7.2. Gastrointestinal
12.7.3. Pulmonary
12.7.4. Neurology
12.7.5. Hematology
12.7.6. Cardio-vascular
12.7.7. Metabolic disorders
12.7.8. Endocrinology
12.7.9. Infectious diseases
12.7.10. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Orphan Drugs Demand Share, 2019-2026
13. Middle East & Africa Orphan Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Orphan Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Orphan Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Speciality Pharmacies
13.4.3. Retail pharmacies
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Orphan Drugs Market Size and Volume Forecast by Type
13.7.1. Oncology
13.7.2. Gastrointestinal
13.7.3. Pulmonary
13.7.4. Neurology
13.7.5. Hematology
13.7.6. Cardio-vascular
13.7.7. Metabolic disorders
13.7.8. Endocrinology
13.7.9. Infectious diseases
13.7.10. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Orphan Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Orphan Drugs Market: Market Share Analysis
14.2. Orphan Drugs Distributors and Customers
14.3. Orphan Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sanofi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Alexion Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novo Nordisk
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AstraZeneca
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Eisai
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Daiichi Sankyo
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Bayer
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. GlaxoSmithKline
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Merck
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Johnson & Johnson
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Biogen
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Shire
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Amgen
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
